天大藥業有限公司 董事長兼董事總經理 方文權 謹啓 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 董事會會議日期 天大藥業有限公司（「本公司」）之董事會（「董事會」）謹此公佈，本公司將於2025年8 月28日（星期四）舉行董事會會議，以批准（其中包括）本公司及其附屬公司截至 2025年6月30日止六個月之中期業績。 代表董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 香港，2025年8月15日 於本公告日期，本公司之執行董事為方文權先生（董事長兼董事總經理）和呂文生 先生；非執行董事為鍾濤先生和馮全明先生；而獨立非執行董事則為林日輝先生、 趙崇康先生和冼彥芳博士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | 本月底法定/註冊股本 ...

Company Overview - Tian Da Pharmaceutical focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical industry [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - Tian Da Pharmaceutical utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and expand its market reach [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% compared to the previous year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Tian Da Pharmaceutical's price-to-earnings (P/E) ratio is -4.73, ranking 138th in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 2.79 [3] - The company has underperformed the Hang Seng Index, with a cumulative decline of 20.12% this year, compared to the index's increase of 19.78% [2] Industry Context - The pharmaceutical and biotechnology industry has an average P/E ratio of 2.79, with a median of 6.7 [3] - Competitors in the industry include other pharmaceutical companies with varying P/E ratios, such as Jingxin Pharmaceutical at 0.86 and Dongrui Pharmaceutical at 3.03 [3]

Summary of Key Points Core Viewpoint - As of July 3, a total of 120 stocks reached their 52-week highs, indicating a strong market performance with notable leaders in the list [1]. Group 1: Top Performers - The top three stocks with the highest increase rates are: - 富誉控股 (Fuyou Holdings) at 90.76%, closing at 0.435 with a peak of 0.475 [1] - 信义能源 (Xinyi Energy) at 65.00%, closing at 1.200 with a peak of 1.980 [1] - 中国三三传媒 (China San San Media) at 42.86%, closing at 1.710 with a peak of 1.900 [1] Group 2: Additional Notable Stocks - Other notable stocks include: - ITE HOLDINGS at 34.21% increase, closing at 0.047 with a peak of 0.051 [1] - 星凯控股 (Xingkai Holdings) at 30.00%, closing at 0.480 with a peak of 0.650 [1] - 北京北辰实业股份 (Beijing Beichen Industrial) at 26.47%, closing at 0.940 with a peak of 1.290 [1] Group 3: Overall Market Trends - The overall trend shows a significant number of stocks achieving new highs, reflecting positive investor sentiment and market conditions [1].

Company Overview - Tian Da Pharmaceutical Co., Ltd. focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical and healthcare sectors [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of Chinese medicine clinic called "Tian Da Clinic" [4] - Tian Da Pharmaceutical utilizes internet technology, big data, and artificial intelligence to integrate online and offline services, providing comprehensive healthcare services [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% year-on-year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.44 times, with a median of 4.53 times [3] - Tian Da Pharmaceutical has a P/E ratio of -5.26 times, ranking 125th in the industry [3] - Comparatively, other companies in the sector have P/E ratios ranging from 0.72 times to 4.28 times [3] Recent Stock Performance - As of May 9, the Hang Seng Index increased by 0.4%, closing at 22,867.74 points [1] - Tian Da Pharmaceutical's stock price was 0.162 HKD per share, reflecting an increase of 8.0% with a trading volume of 2,000 shares and a turnover of 326 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.71%, and a year-to-date decline of 11.24%, underperforming the Hang Seng Index's increase of 13.54% [2]

Regulatory Approvals - Tianda Pharmaceuticals received drug registration approval for "Nicorandil for Injection" from the National Medical Products Administration of China[15]. - Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. obtained drug registration approval for "Ibuprofen suspension" from the National Medical Products Administration of China[16]. - In 2024, the Group has received drug registration approvals for 4 new varieties, including pediatric drugs and a cardiocerebrovascular drug, which are expected to drive new growth momentum[75]. Corporate Social Responsibility - Tianda Pharmaceuticals was awarded the "Caring Company" logo for the fourth consecutive year by the Hong Kong Council of Social Service[13]. - Tianda Pharmaceuticals was recognized as a "Happy Company" under the "Happiness-at-Work Promotional Scheme" by the Promoting Happiness Index Foundation[12]. - The Group has conducted over 40 charity clinic sessions and organized numerous TCM-themed activities to promote TCM knowledge in the community[68]. Business Operations and Strategy - The company operates multiple TDMall locations, including in Jordan and Causeway Bay, enhancing its market presence[20][21]. - The Group's strategy includes the "Three Developments" focusing on Chinese medicine, innovative drugs, and quality healthcare services, aiming to consolidate core products and expand sales channels[39][42]. - The Group plans to launch three new products in 2025, enhancing its product pipeline and focusing on R&D for innovative drugs and consumer healthcare products[40][43]. - The Group opened its sixth TDMall globally and fifth in the Greater Bay Area in October 2024, aiming to establish it as an oncology treatment center[45]. - The Group aims to promote a collaborative development model of "drugs + medical services" to enhance the quality of the Chinese medicine business[46]. Financial Performance - The Group's total revenue for the Year was HK$329.9 million, a significant decline from HK$532.1 million in the Previous Financial Year, resulting in increased losses attributable to shareholders from HK$24.2 million to HK$61.4 million[52]. - Revenue from the Pharmaceuticals and medical technologies business was HK$283.9 million, down 39.7% from HK$470.7 million in the Previous Financial Year, primarily due to decreased demand for Tuoen® Ibuprofen and competitive pricing strategies affecting Tuoping® Valsartan capsules[82]. - The loss attributable to shareholders increased from HK$24.2 million to HK$61.4 million, reflecting the overall decline in business performance[89]. Governance and Management - The Company emphasizes corporate governance with various committees including Audit, Remuneration, and Risk Management[5]. - The Company has complied with the Corporate Governance Code during the year, except for the separation of the roles of Chairman and CEO[104]. - The Board consists of 6 male Directors and 1 female Director, including 2 Executive Directors and 3 Independent Non-executive Directors[110]. - The Company has established various committees, including the audit, nomination, remuneration, and risk management committees, primarily composed of INEDs[133]. - The Board has developed and reviewed policies related to Board diversity and shareholder communication[126]. Research and Development - The Group's R&D projects include one Class 1 TCM innovative drug, three Class 3 TCM new drugs, and twelve chemical generic drugs, indicating a rich R&D pipeline[74]. - The Group is focusing on the R&D of traditional Chinese medicine, aiming for stronger R&D, larger markets, and enhanced efficacy through technological advancements and resource growth[64]. - The Group is advancing the Phase II clinical trials of a Class 1 TCM innovative drug for chronic heart failure, highlighting its commitment to innovative medicine[76]. Market Challenges and Outlook - In 2024, the pharmaceutical market faced challenges due to economic uncertainty, with a focus on respiratory infection and antihypertensive drugs struggling to grow as inventory clearance continued post-pandemic[39][42]. - The Chinese medicine segment faced a decline in end-user demand due to the economic environment, impacting trading and production of Chinese medicinal materials[41][43]. - Future market demand is expected to improve as the economy recovers and national policies supporting the pharmaceutical industry are enhanced[46]. Human Resources - As of December 31, 2024, the Group employed approximately 701 employees across Hong Kong, the PRC, and Australia[99]. - The board currently consists of 6 male and 1 female directors, with female representation at approximately 48% at the workforce level[155].

Group 1 - Tian Da Pharmaceutical (00455.HK) closed at HKD 0.136 on April 10, down 12.26% from the previous trading day, with an intraday low of HKD 0.135, marking a new low in nearly a year [1] - The capital flow on that day showed a main inflow of HKD 0.000 million and an outflow of HKD 0.297 million, resulting in a net outflow of HKD 0.30 million [1] Group 2 - Tian Da Pharmaceutical focuses on developing traditional Chinese medicine (TCM) and aims to become a competitive player in drug research, medical technology, and health management [2] - The company is building a comprehensive TCM industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of TCM clinic called "Tian Da Clinic" [2] - Tian Da Pharmaceutical leverages internet technology, big data, and artificial intelligence to integrate online and offline TCM services, providing convenient health services [2] - The product range includes traditional Chinese medicine, chemical drugs, biological products, health products, and medical devices, covering various therapeutic areas [2] - The company is expanding its market presence both domestically in China and internationally, with marketing centers in Shenzhen and Zhuhai, and subsidiaries in Hong Kong and Australia [2] - Tian Da Pharmaceutical aims to meet the growing healthcare demands by collaborating with quality partners and integrating advanced treatment technologies [2]

Financial Performance - TDMall's overall revenue increased to HK$13.0 million in the current year, up from HK$11.2 million in the previous financial period, reflecting a growth of approximately 16.1%[3] - The Group's overall revenue for the year reached HK$532.1 million, an increase from HK$410.0 million in the previous financial period[123] - Loss attributable to shareholders reduced from HK$41 million to HK$24.2 million, indicating improved profitability driven by business performance[32] - The Group's gross profit increased to HK$255.5 million, with a gross profit margin rising from 46.0% to 48.0%[165] - Revenue from the Pharmaceuticals and medical technologies business was HK$470.7 million, up from HK$344.7 million, driven by strong sales of the pediatric drug Tuoen®Ibuprofen[165] - Revenue from the Chinese medicine business decreased to HK$48.4 million from HK$54.1 million due to a stricter credit policy[165] Cash and Liquidity - The Group's cash and cash equivalents as of December 31, 2023, were HK$162.4 million, a decrease from HK$340.3 million as of December 31, 2022, indicating a decline of about 52.2%[14] - The Group's liquidity remains healthy, with no net debt as total borrowings are less than cash and cash equivalents[14] - The Group has unutilized bank loan facilities of HK$148.3 million, with short-term and medium-term bank borrowings of HK$96.5 million and HK$8.4 million respectively[47] - The Group pledged right-of-use assets and property, plant, and equipment with a carrying value of HK$254 million to secure a bank loan facility[38] Product Development and R&D - The Group has seven new products entering the registration stage, with five expected to launch in 2024, which will drive new growth opportunities[9] - The Group plans to launch five new products in 2024, including pediatric drugs and a diabetes treatment, enhancing its product portfolio[8] - R&D expenses decreased significantly from HK$27.1 million to HK$13.1 million, with some projects entering the registration phase expected to start market sales in 2024[31] - The Group's continued investment in research and development is expected to yield new product launches, creating new profit growth drivers[94] - The new liquid-finished dosages production line at the Zhuhai Jinwan R&D and production base was completed and operational in the first half of 2023 to meet market demand for Tuoen®Ibuprofen[141] Market Expansion and Strategy - The Group is focusing on international market expansion, particularly in ASEAN, Africa, and BRICS countries, while enhancing its marketing network for Chinese medicine and health products[33] - The Group aims to capitalize on TCM policies for high-quality development, focusing on expanding both domestic and international markets[11] - The Group established a nationwide marketing network covering 31 provinces, enhancing market penetration in lower-tier markets[26] - Tianda Pharmaceuticals plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the region by 2025[59] - The Group is actively constructing and developing a series of TCM health products, aiming for stronger R&D, larger markets, and enhanced efficacy in the TCM sector[116] Corporate Governance and Structure - The Board is responsible for corporate governance duties, including reviewing policies and compliance with legal and regulatory requirements[191] - The Company has established a board independence evaluation mechanism to ensure the independence of non-executive directors[189] - The remuneration committee consists of three INEDs and one Executive Director, with Mr. Chiu Sung Hong serving as the Chairman[198] - The committee held three meetings during the year to review remuneration packages for Executive Directors, Non-executive Directors, INEDs, and senior management[199] Awards and Recognition - The company received the "Happy Company" status under the "Happiness-at-Work Promotional Scheme," reflecting its commitment to employee well-being[60] - The Group has been awarded the "Caring Company" logo for three consecutive years, reflecting its commitment to social responsibility[100] - The Group received the "ESG Award" from Television Broadcast Limited, highlighting its commitment to environmental, social, and governance standards[78] - Tuoen®Ibuprofen received the "Most Valuable Product in China's Pharmacy Chains" award, with seven products currently in the R&D registration stage, five of which are expected to launch in 2024[115] Acquisitions and Investments - The acquisition of the remaining 45% interest in Yunnan Meng Sheng Pharmaceutical Co., Ltd. was completed during the year[38] - The acquisition allows Tianda Pharmaceuticals (Yunnan) to become an indirectly wholly-owned subsidiary, enhancing business strategy implementation and expansion plans[179] - Tianda Biotech Limited subscribed to an investment fund for a total amount of HK$10.0 million on April 19, 2023[173] - The total consideration for the acquisition of Tianda Pharmaceuticals (Yunnan) reflects a strategic move to consolidate operations and enhance market presence[176]

Annual Report 2022 (For The Nine Months Ended 31 December 2022) CONTENTS 目錄 2 Corporate Information 公司資料 5 Corporate Structure 企業架構 8 Biographical Details of Directors 董事簡歷 11 Report of the Chairman 董事長報告 13 Management Discussion and Analysis 管理層討論與分析 21 Corporate Governance Report 企業管治報告 44 Report of the Directors 董事會報告 58 Independent Auditor’s Report 獨立核數師報告 65 Consolidated Statement of Profit or Loss and 綜合損益及其它全面收益表 Other Comprehensive Income 67 Consolidated Statement of Financial Position 綜合財務狀況表 69 Co ...

Financial Performance - The Group's overall revenue improved by 5.6% to HK$249.9 million during the Reporting Period[10] - EBITDA increased from a loss of HK$6.9 million in the previous year to a profit of HK$2.3 million[10] - The Group recorded a revenue growth of 5.6%, increasing from HK$236.5 million to HK$249.9 million in the Reporting Period[29] - Gross profit rose from HK$110.9 million to HK$122.2 million, attributed to improved sales efficiency and cost control[29] - Other income and net gains increased significantly from HK$2.1 million to HK$7.0 million, boosted by government subsidies and higher interest income[31] - Loss attributable to owners of the parent decreased from HK$17.9 million to HK$16.3 million, indicating improved operating performance[32] - The overall revenue increased by 5.6% to HKD 249.9 million for the six months ended September 30, 2022[64] - EBITDA turned from a loss of HKD 6.9 million in the previous year to a profit of HKD 2.3 million in the current period[64] - Gross profit for the same period was HK$122.19 million, compared to HK$110.92 million in 2021, indicating an increase of about 10.5%[100] - Loss for the period attributable to owners of the parent was HK$16.35 million, a decrease from HK$17.95 million in the previous year, reflecting a reduction of approximately 8.5%[102] Research and Development - R&D expenses surged by 260% year-on-year to HK$12.0 million, reflecting a significant investment in innovation[10] - The Group has 22 R&D projects underway, including innovative Chinese medicine and healthcare products[21] - R&D expenditure increased by 260% year-on-year to HKD 12 million, reflecting a significant commitment to innovation[64] - R&D expenses surged from HK$3.3 million to HK$12.0 million, reflecting steady progress in innovation[30] - The new R&D and production base in Zhuhai commenced production, enhancing manufacturing quality and efficiency[26] - The company is focusing on developing innovative traditional Chinese medicine products and expanding its herbal medicine trade[79] Product Sales and Market Expansion - Sales of the core product Tuoping® reached HK$92.3 million, a year-on-year increase of approximately 21%[12] - Sales of Tuoen® reached HK$64.0 million, representing a year-on-year growth of approximately 70%[12] - The Chinese medicine segment experienced a 44% decrease in sales due to pandemic-related disruptions, but efforts to expand product offerings continue[14] - The company aims to enhance its market share and brand influence by expanding product sales across the entire market[67] - The company aims to strengthen its core product brands, focusing on cardiovascular and pediatric products, while expanding its CDMO/CMO business to increase revenue[79] - The company is focusing on expanding its market presence in Mainland China, Hong Kong, and Australia, leveraging its diverse product offerings[145] Financial Position and Cash Flow - The financial position remains strong with cash and cash equivalents of HK$232.9 million and no net debt as of September 30, 2022[50] - As of September 30, 2022, the company had cash and cash equivalents totaling HK$232.9 million, a decrease from HK$334 million as of March 31, 2022, with approximately 96.1% denominated in RMB[90] - The company has unused bank loan facilities amounting to HKD 42.8 million as of September 30, 2022[90] - The company reported a net cash outflow from investing activities of HK$36,790,389, which is a significant increase from HK$23,518,171 in the prior year[110] - The company experienced a net decrease in cash and cash equivalents of HK$70,822,070, compared to a decrease of HK$38,574,186 in the same period last year[110] Corporate Strategy - The strategy includes increasing sales network coverage and expanding CDMO/CMO businesses to drive revenue growth[34] - The Group plans to strengthen TDMall's operations and expand through self-construction, franchising, and mergers and acquisitions[36] - The company plans to leverage policies promoting traditional Chinese medicine to enhance its market presence and expand its product offerings[79] - The company aims to leverage the growing pharmaceutical market driven by population growth and increasing health awareness[77] Taxation and Compliance - The Group did not generate any assessable profits in Hong Kong and Australia during the period, resulting in no provision for profits tax in these regions[165] - The applicable corporate income tax rate in Mainland China is 25%, with Tianda Pharmaceuticals (Zhuhai) and Meng Sheng Pharmaceutical benefiting from a preferential tax rate of 15%[165] - The total tax credit for the period amounted to HK$1,073,339, compared to HK$199,181 in the previous period[167] Employee and Operational Information - The company employs approximately 699 staff across Hong Kong, China, and Australia, with compensation determined based on market terms and employee qualifications[96] - The company is committed to enhancing the customer experience through the integration of online and offline services in its operations[80] Asset Management - The net carrying amount of goodwill as of 30 September 2022 was HK$94,645,257, down from HK$106,213,773 at the beginning of the period[179] - The Group acquired property, plant, and equipment worth HK$19,719,477, a decrease from HK$24,697,191 in the previous period[174] - The Group disposed of property, plant, and equipment with a carrying amount of HK$109,618, resulting in a gain on disposal of HK$667,512[174]